Fiche centre
Oklahoma Medical Research Foundation; MS Center of Excellence
Oklahoma City — United States
Essais liés3clinical trials
VilleOklahoma Citylocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02807285
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Ocrelizumab | SEP | Phase 3 | NCT01194570 | ORATORIO — A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04586010 | FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |